<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04409236</url>
  </required_header>
  <id_info>
    <org_study_id>RG1007577</org_study_id>
    <secondary_id>NCI-2020-03442</secondary_id>
    <secondary_id>10432</secondary_id>
    <secondary_id>R01CA253975</secondary_id>
    <nct_id>NCT04409236</nct_id>
  </id_info>
  <brief_title>Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking</brief_title>
  <official_title>Randomized Trial of a Smartphone Application to Help Cancer Patients Stop Smoking (Quit2Heal)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Cancer Society, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial compares the Quit2Heal smoking cessation smartphone application (app) to&#xD;
      the QuitGuide app in helping cancer patients quit smoking. Both apps provide tools to cope&#xD;
      with urges to smoke, step-by-step guides for quitting smoking, help in planning for quitting&#xD;
      and staying tobacco-free, and scientifically-based recommendations for how to select&#xD;
      medications that aid in smoking cessation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive the Quit2Heal app and are encouraged to use it frequently. During the&#xD;
      entire 12-month follow-up period, the app will remain fully available anytime study&#xD;
      participants wish to use it.&#xD;
&#xD;
      ARM II: Patients receive the QuitGuide app and are encouraged to use it frequently. During&#xD;
      the entire 12-month follow-up period, the app will remain fully available anytime study&#xD;
      participants wish to use it.&#xD;
&#xD;
      After randomization, patients are followed up at 3, 6, and 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with 30-day cigarette smoking cessation at 12 months.</measure>
    <time_frame>At 12 months after randomization</time_frame>
    <description>No smoking at all in the past 30 or more days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with 30-day cigarette smoking cessation at 3 months.</measure>
    <time_frame>At 3 months after randomization</time_frame>
    <description>No smoking at all in the past 30 or more days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with 30-day cigarette smoking cessation at 6 months.</measure>
    <time_frame>At 6 months after randomization</time_frame>
    <description>No smoking at all in the past 30 or more days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">422</enrollment>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (Quit2Heal app)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive the Quit2Heal app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (QuitGuide app)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive the QuitGuide app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Quit2Heal</intervention_name>
    <description>Use Quit2Heal app</description>
    <arm_group_label>Arm I (Quit2Heal app)</arm_group_label>
    <other_name>Quit2Heal App</other_name>
    <other_name>Quit2Heal Smartphone App</other_name>
    <other_name>Quit2Heal Smartphone Application</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>QuitGuide</intervention_name>
    <description>Use QuitGuide app</description>
    <arm_group_label>Arm II (QuitGuide app)</arm_group_label>
    <other_name>QuitGuide App</other_name>
    <other_name>QuitGuide Smartphone App</other_name>
    <other_name>QuitGuide Smartphone Application</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (Quit2Heal app)</arm_group_label>
    <arm_group_label>Arm II (QuitGuide app)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with cancer within the past 12 months or currently receiving or planning to&#xD;
             receive cancer treatment in the next 3 months&#xD;
&#xD;
          -  Smoked a cigarette (even a puff) in the past 30 days&#xD;
&#xD;
          -  Interested in learning skills to quit smoking&#xD;
&#xD;
          -  Willing to be randomly assigned to either smartphone application&#xD;
&#xD;
          -  Live in the United States and will remain in the United States (US) for the next 12&#xD;
             months&#xD;
&#xD;
          -  Have at least daily access to their own smartphone&#xD;
&#xD;
          -  Know how to download a smartphone application&#xD;
&#xD;
          -  Be willing and able to read English&#xD;
&#xD;
          -  Not currently (i.e., within past 30 days) using other smoking cessation interventions&#xD;
&#xD;
          -  Have never participated in our prior research trials&#xD;
&#xD;
          -  Have never used the National Cancer Institute (NCI)'s QuitGuide app&#xD;
&#xD;
          -  Being willing to complete a follow-up survey at 3, 6, and 12 months post-randomization&#xD;
&#xD;
          -  Providing email, phone number(s), and mailing address&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently (i.e., within past 30 days) using other smoking cessation interventions&#xD;
&#xD;
          -  Has participated in our prior research trials&#xD;
&#xD;
          -  Has used the NCI's QuitGuide app&#xD;
&#xD;
          -  Not willing to complete a follow-up survey at 3, 6, and 12 months post-randomization&#xD;
&#xD;
          -  Not providing email, phone number(s), and mailing address&#xD;
&#xD;
          -  Current use of Food and Drug Administration (FDA)-approved quit smoking medications:&#xD;
             nicotine patch, nicotine gum, nicotine lozenge, nicotine nasal spray, nicotine&#xD;
             inhaler, Chantix (varenicline), or Wellbutrin (Zyban/bupropion)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Bricker</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Bricker</last_name>
    <phone>877-250-6641</phone>
    <email>quit2heal@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jamie Ostroff</last_name>
      <phone>646-888-0041</phone>
      <email>ostroffj@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Jamie Ostroff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Bricker</last_name>
      <phone>877-250-6641</phone>
      <email>quit2heal@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Bricker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

